[Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience].
V A ZherebtsovaVladimir VorobyevE G GemdzhianM A UlyanovaM V ChernikovV L IvanovaOlga VinogradovaVadim V PtushkinPublished in: Terapevticheskii arkhiv (2021)
Our analysis confirmed the high efficiency of KRd in the treatment of RRMM in real-life practice. Early correction of therapy with insufficient effectiveness of the first line made it possible to implement the strategy of high-dose consolidation and autoHSCT in a larger percentage of patients with MM.
Keyphrases
- multiple myeloma
- high dose
- high efficiency
- newly diagnosed
- end stage renal disease
- low dose
- ejection fraction
- stem cell transplantation
- randomized controlled trial
- primary care
- healthcare
- prognostic factors
- systematic review
- acute myeloid leukemia
- acute lymphoblastic leukemia
- chronic kidney disease
- stem cells
- patient reported outcomes
- diffuse large b cell lymphoma
- combination therapy